Siapa Kami
Peluang yang Tidak Bisa Lagi Diabaikan oleh Industri
Lingkungan riset klinis di Indonesia sedang mengalami transformasi nyata:
Pembangunan infrastruktur riset yang kuat melalui pendirian Clinical Research Center (CRC) dan Clinical Research Unit (CRU).
Proses yang disederhanakan untuk waktu penyelesaian dan persetujuan regulasi yang lebih cepat.
- Peningkatan signifikan dalam jumlah peneliti dan investigator bersertifikasi serta terlatih GCP (Good Clinical Practice).
- Akses langsung ke basis populasi pasien yang sangat besar dan beragam yang belum pernah ada sebelumnya.
Visi Kami
To be Indonesia’s leading catalyst for world-class clinical trial excellence, connecting international standards with local expertise through knowledge transfer to build a clinical trials ecosystem across the archipelago and provide early access for patients to advanced therapy.
Misi Kami
Nusa Trials memberdayakan ekosistem penelitian klinis Indonesia dengan cara:
- Building sustainable capacity through comprehensive training and mentorship programs.
- Facilitating culturally and professionally meaningful partnerships.
- Advancing clinical trials standards by combining global best practices with deep understanding of Indonesia’s healthcare landscape.
- Expanding healthcare access by bringing clinical trials to Indonesian patients.
- Strengthening Indonesia’s position as a premier destination for ethical, high-quality clinical trials.
Meet Our Founders & Experts
Orang-orang di balik NusaTrials memadukan puluhan tahun kepemimpinan riset klinis internasional, keahlian riset yang mendalam, serta keyakinan bersama yang tulus bahwa Indonesia ditakdirkan untuk menjadi pusat pengembangan obat global.
Martijn Wallert has spent more than two decades at the forefront of international clinical research, first as a senior executive across European and global industries, and then as Founder of two internationally recognized contract research organizations.
At Julius Clinical, Martijn led the organization through a period of significant strategic growth, securing a major growth investment from Ampersand Capital Partners and executing a landmark cross-Atlantic merger with Peachtree BioResearch Solutions. Under his leadership, Julius Clinical expanded to support over 130 clinical trials in approximately 40 countries, enrolling more than 200,000 patients in complex therapeutic areas including CNS, cardiometabolic disease, and rare diseases.
In parallel, Martijn co-founded and served as Co-Founder of Cohortias, an international CRO purpose-built to bring clinical research access to the underserved populations of Latin America. Martijn brings to Nusa Trials a rare combination: operational depth in building global-standard research infrastructure, strategic expertise in emerging market clinical development, and an unshakeable personal commitment to expanding patient access.
“I have seen, from the inside and from the most personal place possible, what it means to have access to a clinical trial and what it costs when you don’t. That is why Nusa Trials exists.”
Doctor Raka is a physician and public health strategist with a singular focus: making high-quality healthcare work in the Indonesian context not around it.
A graduate of Harvard Medical School, Raka has built his career at the intersection of clinical medicine, health systems design, and cross-sector collaboration. His research at Harvard examined the structural conditions for effective multi-stakeholder partnerships in resource-limited settings. His professional track record spans frontline clinical practice, healthcare financial oversight, and consultant roles with US-based global biotech companies, where he led clinical trial expansion and commercial market development across Southeast Asia. That combination, scientific rigors, regulatory fluency, and deep operational knowledge of Indonesian healthcare facilities, communities, and institutions is essential. It is also precisely what the role of Co-Founder demands.
As the bridge between international standards and Indonesian realities, Raka ensures that what Nusa Trials delivers is not a foreign model adapted for Indonesia, but a research infrastructure genuinely designed from within it.
“Global-standard clinical research only works in Indonesia if it is genuinely built for Indonesia not adapted to it. That is the difference between a foreign operation and a real partner.”
Jan brings 30 years of pharmaceutical industry experience across Europe and Asia, with a career grounded in commercial roles, corporate development, and strategic partnerships. He has worked for and with multinational corporations as well as early and clinical-stage biotech companies across vaccines, gene therapy, and biologics in cardiometabolic, CNS, infectious, and autoimmune diseases. He is also the founder of a data science and machine learning company building rare disease diagnostic tools and digital biomarkers for clinical trial endpoints.
As Co-Founder, Jan is responsible for the full spectrum of commercial activity from initial sponsor engagement and feasibility through to long-term partnership development with CROs, pharmaceutical companies, and biotech seeking a credible, high-quality entry into the Indonesian market. His approach is grounded in the same principle that defines Nusa Trials as a whole: that trust is built through consistent delivery, not through promises.
“Our commercial proposition is simple we offer sponsors something the market has not had before: a single, accountable, global-standard partner across multiple sites in Indonesia. Reliable, transparent, and built to grow.”
Professor John J.P. Kastelein is one of the world’s foremost authorities on cardiovascular medicine and lipoprotein biology, a scientist whose career has produced over 1,300 peer-reviewed publications, an H-index exceeding 122, and more than 74,000 academic citations. His name appears in the most significant cardiovascular outcome trials of the modern era, and his research has directly shaped how the world understands and treats atherosclerotic vascular disease. Professor Kastelein held the Strategic Chair of Genetics of Cardiovascular Disease at Amsterdam UMC for decades. In 1989, he founded the Lipid Research Clinic at the AMC now a tertiary referral centre serving over 5,000 patients annually. He is a Fellow of the European Society of Cardiology, a member of the Royal Dutch Society for Medicine & Physics, and has served on the steering committees of numerous landmark cardiovascular intervention trials.
A serial founder as well as a scientist, Professor Kastelein co-founded Amsterdam Molecular Therapeutics (gene therapy), Dezima Pharma (dyslipidemia), and in 2019 co-founded New Amsterdam Pharma a clinical-stage company developing transformative therapies for cardiometabolic disease. He is also Co-Founder of the Vascular Research Network (VRN), a site management organization comprising over 50 hospitals across Europe making him uniquely qualified to advise Nusa Trials on the architecture and governance of a multi-site SMO.
“What Indonesia represents in the global cardiovascular and cardiometabolic research landscape is extraordinary a large, largely unstudied population with a high disease burden and a healthcare system that is rapidly maturing. This is not a future opportunity. It is a present one.”